Novo Nordisk's key formulation patent (US 9,714,283, filed 2013) covers the phosphate-buffered solution used in Ozempic and Wegovy, with specific pH ranges and phenol concentrations
,
A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes
If proven safe and effective, these patches may offer a more convenient, less invasive option for people who use GLP-1 medications in the future.
Training consistency, diet quality, and baseline carnitine status strongly influence what you notice
When compared with placebo, the difference becomes noticeable but still limited